Limit drug costs to negotiated prices for all U.S. consumers.

limiting drug costs to those negotiated prices for all U.S. consumers

Schrier promises to cap consumer drug costs at negotiated rates.

Dr. Kim Schrier Doubles Down on Healthcare in First Two Ads + Comprehensive Reform Proposal | Kim Schrier
campaign · press_release · model gpt-5.4-mini

The Supreme Court's May 18, 2026 order list places AstraZeneca v. Kennedy, Janssen Pharmaceuticals v. Kennedy, Bristol Myers Squibb v. Kennedy, Novo Nordisk v. Kennedy, Boehringer Ingelheim v. HHS, and Novartis Pharmaceuticals v. Kennedy under 'Certiorari Denied.'

Within the lookback window, the Court denied review in several manufacturer cases challenging the Medicare drug-negotiation program, leaving the Medicare-only program in place. This supports partial delivery, not an all-consumer negotiated-price limit.

partial later_term

051826zor_h315.pdf
secondary · model gpt-5.5 · confidence 86%

AP reported that the Supreme Court rejected appeals from pharmaceutical companies objecting to Medicare price negotiations; the Inflation Reduction Act requires negotiation for certain high-cost drugs in Medicare, with first deals going into effect in 2026.

Strong reporting explains the official order's context: the lookback-window court action preserved negotiated prices for Medicare drugs only. It does not show negotiated prices for all U.S. consumers.

partial later_term

Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations
secondary · model gpt-5.5 · confidence 83%

CMS selected 15 high-cost prescription drugs covered under Medicare Part D and, for the first time, drugs payable under Medicare Part B. Negotiations occur in 2026, with negotiated prices effective January 1, 2028; second-cycle prices take effect January 1, 2027.

CMS implementation continues and expands Medicare drug negotiations, but the program remains limited to Medicare coverage rather than all U.S. consumers.

partial later_term

CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs | CMS
secondary · model gpt-5.5 · confidence 90%

CMS said the Inflation Reduction Act gives Medicare authority to directly negotiate certain high-expenditure drug prices; CMS reached negotiated Maximum Fair Prices for 10 Medicare Part D drugs effective January 1, 2026, on behalf of people with Medicare.

This is concrete partial delivery: negotiated prices exist for selected Medicare Part D drugs, but the source confines the benefit to Medicare, not all consumers.

partial later_term

Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026
secondary · model gpt-5.5 · confidence 93%

Schrier's office said she helped pass the Inflation Reduction Act and listed drug-cost provisions including allowing Medicare to negotiate lower drug prices, capping Medicare out-of-pocket costs, capping insulin costs for seniors, and penalizing drug companies for unfair price hikes.

Schrier took concrete action for partial drug-cost negotiation through Medicare. The described provisions fall short of negotiated-price limits for all U.S. consumers.

partial later_term A for effort

Rep. Schrier Votes to Bring Down Health Care and Prescription Drug Costs, Invest in Combating Climate Change
secondary · model gpt-5.5 · confidence 91%

The House Clerk records Roll Call 420 on H.R. 5376 as passed, 220 yeas to 207 nays. The vote list records Schrier, Democratic, Washington, as Yea.

Official roll-call proof that Schrier voted for the Inflation Reduction Act, the enacted source of Medicare drug negotiations. This supports partial delivery in a later term.

partial later_term A for effort

Roll Call 420 | Bill Number: H.R. 5376
secondary · model gpt-5.5 · confidence 94%

The House Clerk records H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, as passed by the House, 230 yeas to 192 nays. The vote list records Schrier, Democratic, Washington, as Yea.

During Schrier's first House term, she voted for a stronger bill aimed at broad negotiated drug prices. Because it passed only the House and did not become law, this is serious effort, not delivery.

never same_term A for effort

Roll Call 682 | Bill Number: H.R. 3
secondary · model gpt-5.5 · confidence 92%

Congress.gov lists H.R. 3 with status 'Passed House' and latest Senate action on September 8, 2020: read the second time and placed on the Senate Legislative Calendar, Calendar No. 521.

The broad all-consumer-style House bill stalled in the Senate and was not enacted during Schrier's first term, so the full promise was not delivered then despite effort.

never same_term

Actions - H.R.3 - 116th Congress (2019-2020): Elijah E. Cummings Lower Drug Costs Now Act
secondary · model gpt-5.5 · confidence 93%